Fenbendazole for Cancer Treatment in Humans
Fenbendazole is NOT approved by the FDA or EMA for cancer treatment in humans and should not be used outside of clinical trials. 1, 2
Current Regulatory and Clinical Status
Fenbendazole is a veterinary anthelmintic agent approved only for treating parasitic infections in animals such as dogs and pigs. 1, 2 Its pharmacokinetics, safety profile, optimal dosing, and therapeutic efficacy in humans remain undocumented in peer-reviewed medical literature. 2
Evidence Base
Preclinical Data
- Laboratory studies demonstrate fenbendazole inhibits proteasomal activity, induces G2/M cell cycle arrest, triggers apoptosis, and causes endoplasmic reticulum stress in cancer cell lines including non-small cell lung cancer and cervical cancer. 3, 4
- Animal models show tumor growth inhibition in immunodeficient mice, with combination therapy (fenbendazole plus diisopropylamine dichloroacetate) achieving 50% complete tumor regression in lung cancer xenografts. 5
Human Clinical Evidence
There are NO published clinical trials demonstrating safety or efficacy of fenbendazole for cancer treatment in humans. 2
Documented Harms in Cancer Patients
Severe Hepatotoxicity
- A patient with advanced non-small cell lung cancer developed severe drug-induced liver injury after one month of self-administered fenbendazole, requiring drug discontinuation for resolution. 6
- A 47-year-old woman with metastatic colon cancer on immunotherapy developed severe hepatocellular injury (Roussel Uclaf Causality Assessment Method score of 8, indicating "probable" causation) after increasing her fenbendazole dose. 7
- Critically, neither patient experienced tumor shrinkage despite taking fenbendazole. 6
Diagnostic Confusion
Fenbendazole-induced liver injury mimics immune checkpoint inhibitor hepatitis, potentially leading to inappropriate immunosuppression or delays in effective cancer treatment. 7
Social Media Misinformation Risk
Patients are self-administering fenbendazole based on unverified social media claims, often at high doses without medical supervision. 6, 7 This represents a significant patient safety concern, as sources of medical information on platforms like Twitter and Facebook are frequently unproven and difficult for non-medical professionals to evaluate accurately. 6
Clinical Recommendations
For Oncologists
- Proactively ask all cancer patients about self-administration of fenbendazole, dietary supplements, herbs, or other bioactive compounds during every visit. 6, 7
- Obtain detailed medication histories when patients present with unexplained liver enzyme elevations or other adverse events. 7
- Use structured causality assessment tools (e.g., Roussel Uclaf Causality Assessment Method) to differentiate drug-induced liver injury from immune-related adverse events. 7
- Counsel patients about the lack of human safety data and documented hepatotoxicity risk. 2, 6, 7
For Patients
Do not use fenbendazole for cancer treatment. Standard evidence-based cancer therapies have proven survival benefits through rigorous clinical trials. [8-9] Fenbendazole has caused documented liver injury in cancer patients without demonstrating tumor response. 6, 7
Future Research Needs
Clinical trials are essential to assess fenbendazole's potential anticancer effects, optimal doses, therapeutic regimens, and tolerance profiles before any consideration for human use. 2 Until such data exist, fenbendazole remains an unapproved veterinary medication with documented human toxicity and no proven cancer benefit.